Latest Insider Transactions at 89bio, Inc. (ETNB)
This section provides a real-time view of insider transactions for 89bio, Inc. (ETNB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of 89bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of 89bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Jun 02
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
22,138
+0.44%
|
$398,484
$18.77 P/Share
|
|
May 28
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
123,505
+2.44%
|
$2,223,090
$18.77 P/Share
|
|
May 27
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
35,535
+0.73%
|
$639,630
$18.76 P/Share
|
|
May 26
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
48,377
+1.0%
|
$870,786
$18.03 P/Share
|
|
May 17
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$147,000
$21.61 P/Share
|
|
May 17
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Apr 21
2021
|
Gregory Grunberg Director |
SELL
Open market or private sale
|
Direct |
850
-100.0%
|
$22,950
$27.6 P/Share
|
|
Apr 19
2021
|
Ryan Martins Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-57.14%
|
$250,000
$25.0 P/Share
|
|
Apr 19
2021
|
Ryan Martins Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.36%
|
$30,000
$3.11 P/Share
|
|
Apr 16
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$168,000
$24.22 P/Share
|
|
Apr 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Apr 01
2021
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
628,277
+28.83%
|
$14,450,371
$23.68 P/Share
|
|
Mar 16
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$168,000
$24.2 P/Share
|
|
Mar 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Feb 23
2021
|
Michael R Hayden |
BUY
Exercise of conversion of derivative security
|
Direct |
80,904
+24.39%
|
$161,808
$2.32 P/Share
|
|
Feb 16
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$161,000
$23.39 P/Share
|
|
Feb 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Feb 05
2021
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Feb 05
2021
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Feb 05
2021
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Feb 05
2021
|
Ram Waisbourd Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+50.0%
|
-
|
|
Feb 05
2021
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jan 19
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$147,000
$21.16 P/Share
|
|
Jan 19
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Dec 16
2020
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$189,000
$27.04 P/Share
|
|
Dec 16
2020
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Nov 16
2020
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$189,000
$27.39 P/Share
|
|
Nov 16
2020
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Nov 16
2020
|
Quoc Le Nguyen |
SELL
Open market or private sale
|
Direct |
4,548
-100.0%
|
$127,344
$28.11 P/Share
|
|
Nov 16
2020
|
Quoc Le Nguyen |
BUY
Exercise of conversion of derivative security
|
Direct |
4,548
+50.0%
|
$13,644
$3.11 P/Share
|
|
Nov 16
2020
|
Gregory Grunberg Director |
BUY
Other acquisition or disposition
|
Direct |
850
+50.0%
|
-
|
|
Nov 16
2020
|
Gregory Grunberg Director |
SELL
Other acquisition or disposition
|
Indirect |
850,000
-32.68%
|
-
|
|
Nov 16
2020
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
5,944
+50.0%
|
-
|
|
Nov 16
2020
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
850,000
-32.68%
|
-
|
|
Sep 21
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
275,000
-6.87%
|
$7,700,000
$28.0 P/Share
|
|
Sep 17
2020
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,300,000
+21.54%
|
$36,400,000
$28.0 P/Share
|
|
Jul 08
2020
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
275,000
+7.41%
|
$7,425,000
$27.5 P/Share
|
|
Nov 13
2019
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,661,214
+34.45%
|
-
|
|
Nov 13
2019
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,555,716
+38.96%
|
-
|
|
Nov 11
2019
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+50.0%
|
$24,000,000
$16.0 P/Share
|
|
Nov 11
2019
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
837,500
+36.63%
|
$13,400,000
$16.0 P/Share
|